Abstract
Watson for Oncology (WFO) is a artificial intelligence clinical decision-support system with evidence-based treatment options for oncologists. WFO has been gradually used in China, but limited reports on whether WFO is suitable for Chinese patients. This study aims to investigate the concordance of treatment options between WFO and real clinical practice for Cervical cancer patients retrospectively. We retrospectively enrolled 300 cases of cervical cancer patients. WFO provides treatment options for 246 supported cases. Real clinical practice were defined as concordant if treatment options were designated “recommended” or “for consideration” by WFO. Concordance of treatment option between WFO and real clinical practice was analyzed statistically. The treatment concordance between WFO and real clinical practice occurred in 72.8% (179/246) of cervical cancer cases. Logistic regression analysis showed that rural registration residences, advanced age, poor ECOG performance status, stages II-IV disease have a remarkable impact on consistency. The main reasons attributed to the 27.2% (67/246) of the discordant cases were the substitution of nedaplatin for cisplatin, reimbursement plan of bevacizumab, surgical preference, and absence of neoadjuvant/adjuvant chemotherapy and PD-1/PD-L1 antibodies recommendations. WFO recommendations were in 72.8% of concordant with real clinical practice for cervical cancer patients in China. However, several localization and individual factors limit its wider application. So, WFO could be an essential tool but it cannot currently replace oncologists. To be rapidly and fully apply to cervical cancer patients in China, accelerate localization and improvement were needed for WFO.
Highlights
Artificial intelligence (AI) is the frontier and dominating terrain of Information Technology which able to simulate human mental status and cognitive function (Jiang et al, 2017)
Watson for Oncology for Cervical Cancer Patients in China developed by IBM Co.Ltd in United States
Whether Watson for Oncology (WFO) was fit for Chinese cancer patients, especially cervical cancer patients
Summary
Artificial intelligence (AI) is the frontier and dominating terrain of Information Technology which able to simulate human mental status and cognitive function (Jiang et al, 2017). With the development of AI and medical diagnosis technology, clinical decision-support systems (CDSS) with intelligent diagnostic function has become one of the important issues of science for medical information (Meyer et al, 2018). Watson for Oncology (IBM) is a representative AI CDSS that. Watson for Oncology for Cervical Cancer Patients in China developed by IBM Co.Ltd in United States. WFO can provide a reasonable individualized treatment plan for cancar patients by obtaining valuable information from medical records. WFO first officially landed in China in 2016, until now, more than 80 hospitals use WFO as an important medical diagnostic tool for individualized treatment of tumor (IBM, 2017). WFO can provide counseling services for almost all cancer patients. Whether WFO was fit for Chinese cancer patients, especially cervical cancer patients
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.